Peter Anastasiou was named President and Chief Executive Officer of Harmony Biosciences Holdings, Inc., effective January 1, 2027. As of November 6, 2026, Harmony Biosciences Holdings, Inc. has reported 5 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 2, 2026 to October 30, 2026, naming 4 appointments and 1 departure (Form 8-K, October 30, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Harmony Biosciences Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Peter Anastasiou · Role: President and Chief Executive Officer · Effective: 2027-01-01 · 8-K/A, 2026-10-30
- · In / out: In · Person: Peter Anastasiou · Role: President and Chief Executive Officer · Effective: 2027-01-01 · 8-K, 2026-10-13
- · In / out: In · Person: Stephen Mollichella · Role: Principal Financial Officer · Effective: 2026-07-16 · 8-K, 2026-07-16
- · In / out: In · Person: Glenn Reicin · Role: Chief Financial Officer · Effective: 2026-04-14 · 8-K, 2026-04-14
- · In / out: Out · Person: Antonio Gracias · Role: Director · 8-K, 2026-04-02
Harmony Biosciences Holdings, Inc. reported changes in 5 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-02 to 2026-10-30. They name 4 people, with 4 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Harmony Biosciences Holdings, Inc. files it.
Also on the record for Harmony Biosciences Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 12.6% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.08% of the class | 5%+ stakes | Source |
| July 28, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 11.3% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 5.4% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Antonio J. Gracias | 3.2% of the class | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 6.7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Harmony Biosciences Holdings, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Harmony Biosciences Holdings, Inc. and the records around it.
Harmony Biosciences Holdings, Inc. elsewhere on the record
Companies that share a holder
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
- Vanguard Portfolio Management also filed stake reports on 941 other companies: Newmark Group Inc (Nov 2026), A10 Networks Inc (Oct 2026), ADT Inc (Oct 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Harmony Biosciences Holdings, Inc.
Get an email when Harmony Biosciences Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Harmony Biosciences Holdings, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Harmony Biosciences Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Harmony Biosciences Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-30 | In | President and Chief Executive Officer | 2027-01-01 | 8-K/A, 2026-10-30 | |
| 2026-10-13 | In | President and Chief Executive Officer | 2027-01-01 | 8-K, 2026-10-13 | |
| 2026-07-16 | In | Principal Financial Officer | 2026-07-16 | 8-K, 2026-07-16 | |
| 2026-04-14 | In | Chief Financial Officer | 2026-04-14 | 8-K, 2026-04-14 | |
| 2026-04-02 | Out | Director | 8-K, 2026-04-02 |
Who leads Harmony Biosciences Holdings, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- President and Chief Executive Officer: Peter Anastasiou, appointed, effective 2027-01-01 (filed 2026-10-30).
- Principal Financial Officer: Stephen Mollichella, appointed, effective 2026-07-16 (filed 2026-07-16).
- Chief Financial Officer: Glenn Reicin, appointed, effective 2026-04-14 (filed 2026-04-14).
- Director: Antonio Gracias, departure reported (filed 2026-04-02). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Harmony Biosciences Holdings, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the President and Chief Executive Officer at Harmony Biosciences Holdings, Inc., with the record behind each one.
Find candidates like President and Chief Executive Officer at Harmony Biosciences Holdings, Inc.Every change, in the filing's words
Appointed: Peter Anastasiou, President and Chief Executive Officer, effective 2027-01-01
On October 12, 2026, the Company also announced that Peter Anastasiou, the Company's current Senior Executive Vice President, Chief Operating Officer, has been appointed by the Board to serve as President and Chief Executive Officer of the Company and as a Class I director of the Company's Board, each effective as of January 1, 2027, at 12:00 a.m.
- On October 12, 2026, the Company announced that Jeffrey M. Dayno, M.D., as part of a leadership succession plan, will be retiring as the Company's President and Chief Executive Officer and stepping down as a Class I director of the Company's Board of Directors (the "Board"), in each case, effective as of December 31, 2026, at 11:59 p.m.
- Eastern Time (the "Resignation Effective Date"), and will serve as a non-executive advisor to the Company through January 2028.
- Eastern Time (the "Appointment Effective Date") to fill the vacancy resulting from Dr. Dayno's resignation.
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- In addition, pursuant to the Separation Agreement, Dr. Dayno is expected to provide consulting services to the Company as an advisor through January 31, 2028.
- During his consultancy, Dr. Dayno will be eligible to receive (x) $500 per hour for any consulting services provided and (y) continued vesting of any Company equity or equity-based awards held by Dr. Dayno as of the Resignation Effective Date based on his continued service with the Company and Harmony Management (or full vesting upon a change in control during the consulting period).
Appointed: Peter Anastasiou, President and Chief Executive Officer, effective 2027-01-01
On October 12, 2026, the Company announced that Peter Anastasiou, the Company's current Chief Operating Officer, has been appointed by the Board to serve as President and Chief Executive Officer of the Company, effective as of January 1, 2027, at 12:00 a.m.
- Departure of President and Chief Executive Officer and Director On October 12, 2026, Harmony Biosciences Holdings, Inc. (the "Company") announced that Jeffrey M. Dayno, M.D., as part of a leadership succession plan, will be retiring as the Company's President and Chief Executive Officer and stepping down as a Class I director of the Company's Board of Directors (the "Board"), in each case, effective as of December 31, 2026, at 11:59 p.m.
- Eastern Time, and will serve as a non-executive advisor to the Company through 2027.
- In addition, the Board appointed Mr. Anastasiou as a Class I director of the Company, effective as of the Appointment Effective Date, to fill the vacancy resulting from Dr. Dayno's resignation from the Board, with a term expiring at the Company's 2027 Annual Meeting of Stockholders and until his successor is elected and qualified, or until his earlier death, resignation or removal.
- Mr. Anastasiou, age 55, has served as the Company's Chief Operating Officer since April 2026.
- He served as Chief Executive Officer and as a member of the board of directors of Capsida Biotherapeutics, a next-generation integrated gene therapy company, from January 2022 to October 2025.
Appointed: Stephen Mollichella, Principal Financial Officer, effective 2026-07-16
On July 16, 2026, the Board of Directors of the Company appointed Stephen Mollichella, the Company's Senior Vice President and Controller, as Interim Principal Financial Officer of the Company, effective as of July 16, 2026.
- Departure of Chief Financial Officer On July 16, 2026, the Company announced that Glenn Reicin, the Company's Chief Financial Officer, will be stepping down as the Company's Chief Financial Officer effective as of July 16, 2026 to pursue other career opportunities.
- In connection with his departure from the Company, on July 16, 2026, the Company and Harmony Biosciences Management, Inc. entered into a Separation Agreement with Mr. Reicin (the "Separation Agreement"), pursuant to which Mr. Reicin will be entitled to receive the severance payments and benefits in accordance with his employment agreement and a pro-rated target bonus, in exchange for a release of claims in favor of the Company and its affiliates and continued compliance with the Separation Agreement and any restrictive covenants.
- Mr. Mollichella brings more than two decades of finance and accounting leadership experience across publicly traded biopharmaceutical and medical technology companies.
- Since joining the Company in 2021, he has played a key role in leading the Company's financial accounting and reporting functions, building the Company's accounting team and key financial systems, overseeing key financial governance and control processes and supporting the Company's business development activities.
Appointed: Glenn Reicin, Chief Financial Officer, effective 2026-04-14
On April 14, 2026, the Company announced that Glenn Reicin has been appointed as Chief Financial Officer of the Company, effective as of April 14, 2026.
- Departure of Chief Financial Officer On April 14, 2026, Harmony Biosciences Holdings, Inc. (the "Company") announced that Sandip Kapadia, the Company's Chief Financial Officer, will be stepping down as the Company's Chief Financial Officer effective as of April 14, 2026 to pursue other career opportunities.
- In connection with his departure from the Company, on April 14, 2026, the Company and Harmony Biosciences Management, Inc. ("Harmony") entered into a Separation Agreement with Mr. Kapadia (the "Separation Agreement"), pursuant to which Mr. Kapadia will be entitled to receive the severance payments and benefits in accordance with his employment agreement and award agreements, in exchange for a release of claims in favor of the Company and its affiliates and continued compliance with the Separation Agreement and any restrictive covenants.
- Mr. Reicin, age 61, previously served as Senior Advisor to Eccogene, Inc. ("Eccogene"), a clinical stage biopharmaceutical company developing small molecule therapeutics for cardiometabolic and inflammatory conditions, from October 2025 to April 2026.
- He also served as Chief Financial Officer at Eccogene from October 2024 to October 2025.
- Prior to joining Eccogene, Mr. Reicin served as Chief Financial Officer and Chief Operating Officer at Alladapt Immunotherapeutics, Inc., from June 2021 to January 2024.
Departing: Antonio Gracias, Director
On March 31, 2026, Antonio Gracias, a Class III director of the Board, notified the Board that he would not stand for re-election as a director of the Company.
- Appointment of Chief Operating Officer; Resignation of Director On April 2, 2026, Harmony Biosciences Holdings, Inc. (the "Company") named Peter Anastasiou the Company's Senior Executive Vice President and Chief Operating Officer ("COO"), effective April 2, 2026.
- In connection with his appointment as COO, on April 2, 2026, Mr. Anastasiou provided notice of his resignation as a Class III member of the board of directors (the "Board") of the Company and any committees thereof, effective as of April 2, 2026.
- Mr. Anastasiou's resignation was not due to any disagreement with the Company or the Board on any matter relating to the operations, policies or practices of the Company.
- Mr. Anastasiou, age 55, has served on the Board since November 2023.
- He also served as Chief Executive Officer and as a member of the board of directors of Capsida Biotherapeutics, a next-generation integrated gene therapy company, from January 2022 to October 2025.
- Prior to Capsida, from November 2009 to December 2021, Mr. Anastasiou served in various roles at Lundbeck, a pharmaceutical company publicly traded on the Copenhagen Stock Exchange, including most recently as Executive Vice President and President of North America, and prior to that as Chief Commercial Officer for the U.S. and Vice President and General Manager for Psychiatry.
Tools for this story
Each opens in a new tab, filled in for Harmony Biosciences Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.